MedCap divests Vitamin D
MedCap AB (publ) has, through its subsidiary Unimedic Pharma AB, signed an agreement to divest the rights to the product Vitamin D to Pharmaprim AB.The sales price and capital gain amount to 20 mSEK and generates a positive one-time effect in the third quarter. In 2021, the product’s sales amounted to 3.2 mSEK and the divestment is expected to have a marginal effect on MedCap’s sales and profitability. The sale supports the focus of the company’s specialty pharma portfolio.